NCT01714726 2021-05-26
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
AstraZeneca
Phase 2 Completed
AstraZeneca
McGill University Health Centre/Research Institute of the McGill University Health Centre